| Literature DB >> 34341332 |
Weijing Wang1, Weilong Li2, Yili Wu1, Xiaocao Tian3, Haiping Duan3, Shuxia Li4, Qihua Tan4,5, Dongfeng Zhang6.
Abstract
Depression is currently the leading cause of disability around the world. We conducted an epigenome-wide association study (EWAS) in a sample of 58 depression score-discordant monozygotic twin pairs, aiming to detect specific epigenetic variants potentially related to depression and further integrate with gene expression profile data. Association between the methylation level of each CpG site and depression score was tested by applying a linear mixed effect model. Weighted gene co-expression network analysis (WGCNA) was performed for gene expression data. The association of DNA methylation levels of 66 CpG sites with depression score reached the level of P < 1 × 10-4. These top CpG sites were located at 34 genes, especially PTPRN2, HES5, GATA2, PRDM7, and KCNIP1. Many ontology enrichments were highlighted, including Notch signaling pathway, Huntington disease, p53 pathway by glucose deprivation, hedgehog signaling pathway, DNA binding, and nucleic acid metabolic process. We detected 19 differentially methylated regions (DMRs), some of which were located at GRIK2, DGKA, and NIPA2. While integrating with gene expression data, HELZ2, PTPRN2, GATA2, and ZNF624 were differentially expressed. In WGCNA, one specific module was positively correlated with depression score (r = 0.62, P = 0.002). Some common genes (including BMP2, PRDM7, KCNIP1, and GRIK2) and enrichment terms (including complement and coagulation cascades pathway, DNA binding, neuron fate specification, glial cell differentiation, and thyroid gland development) were both identified in methylation analysis and WGCNA. Our study identifies specific epigenetic variations which are significantly involved in regions, functional genes, biological function, and pathways that mediate depression disorder.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34341332 PMCID: PMC8329295 DOI: 10.1038/s41398-021-01536-y
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Basic characteristics of the participants.
| Characteristics | Values | Intrapair correlation | |
|---|---|---|---|
| Number of twin pairs | 58 | ||
| Male | 29 (50) | – | – |
| Female | 29 (50) | – | – |
| Age, mean (SD) (years) | 52 (7.5) | – | – |
| Depression score, | 8 (0, 21) | 0.36 | 0.006 |
| Cognitive function score, | 21 (8, 30) | 0.39* | 0.002 |
| BMI, mean (SD), (kg/m2) | 25.18 (3.63) | 0.63** | <0.001 |
| Systolic, | 130 (104, 179) | 0.44* | 0.001 |
| Diastolic, | 82 (62, 100) | 0.31* | 0.020 |
| SUA, mean (SD) (μmol/L) | 302 (95) | 0.52** | <0.001 |
| GLU, M ( | 5.4 (3.60, 10.86) | 0.57** | <0.001 |
| CHOL, mean (SD) (mmol/L) | 4.97 (1.18) | 0.54** | <0.001 |
| TG, M ( | 1.19 (0.20, 5.67) | 0.58** | <0.001 |
| HDLC, M ( | 1.34 (0.66, 2.71) | 0.83** | <0.001 |
| LDLC, mean (SD) (mmol/L) | 2.89 (0.88) | 0.45** | <0.001 |
Continuous variables were presented as mean (standard deviation (SD)) or median (P2.5, P97.5); Categorical variables were presented as numbers with percentages.
BMI body mass index, CHOL total cholesterol, GLU fasting glucose, HDLC high-density lipoprotein cholesterol, LDLC low-density lipoprotein cholesterol, SUA serum uric acid, TG triglyceride.
Fig. 1Circular Manhattan plot for epigenome-wide association study of depression.
The numbers of chromosome and the −log10 of P-values for statistical significance are shown. The dots represent the observed CpG sites.
The results of epigenome-wide association study on depression score (P-value <1 × 10−4).
| Chromosome | Position (bp) | Coefficient | Ensembl gene ID | HGNC symbol | |
|---|---|---|---|---|---|
| chr16 | 90,143,728 | 0.403 | 2.951E−08 | ENSG00000126856 | |
| chr16 | 90,143,720 | 0.402 | 4.592E−08 | ENSG00000126856 | |
| chr16 | 90,143,734 | 0.361 | 4.714E−08 | ENSG00000126856 | |
| chr1 | 2,460,431 | 0.054 | 4.083E−07 | ENSG00000197921 | |
| chr16 | 90,143,752 | 0.311 | 1.753E−06 | ENSG00000126856 | |
| chr4 | 170,696,032 | 0.132 | 2.809E−06 | NA | NA |
| chr4 | 170,696,037 | 0.131 | 3.123E−06 | NA | NA |
| chr7 | 157,794,468 | −0.055 | 3.609E−06 | ENSG00000155093 | |
| chr4 | 170,696,018 | 0.131 | 4.001E−06 | NA | NA |
| chr4 | 170,696,053 | 0.130 | 4.603E−06 | NA | NA |
| chr4 | 170,696,014 | 0.131 | 4.857E−06 | ENSG00000056050 | |
| chr6 | 7,441,817 | 0.061 | 7.444E−06 | ENSG00000124784 | |
| chr17 | 16,540,145 | −0.274 | 9.447E−06 | ENSG00000197566 | |
| chr7 | 157,378,324 | 0.052 | 1.138E−05 | ENSG00000155093 | |
| chr4 | 170,696,062 | 0.128 | 1.172E−05 | ENSG00000056050 | |
| chr1 | 231,296,670 | 0.089 | 1.202E−05 | ENSG00000119283 | |
| chr6 | 7,441,838 | 0.065 | 1.218E−05 | ENSG00000124784 | |
| chr11 | 114,480,748 | 0.041 | 1.337E−05 | ENSG00000137634 | |
| chr1 | 231,296,663 | 0.089 | 1.358E−05 | ENSG00000167333 | |
| chr7 | 157,378,313 | 0.046 | 1.398E−05 | ENSG00000155093 | |
| chr1 | 231,296,660 | 0.089 | 1.555E−05 | ENSG00000185880 | |
| chr11 | 114,480,768 | 0.044 | 1.590E−05 | ENSG00000137634 | |
| chr11 | 130,343,943 | 0.336 | 1.617E−05 | ENSG00000166106 | |
| chr12 | 2,903,455 | −0.058 | 1.622E−05 | ENSG00000256150 | |
| chr7 | 157,378,307 | 0.044 | 1.699E−05 | ENSG00000155093 | |
| chr5 | 140,045,268 | 0.026 | 1.765E−05 | ENSG00000120314 | |
| chr18 | 18,627,551 | −0.040 | 1.910E−05 | ENSG00000124784 | |
| chr11 | 130,343,954 | 0.333 | 2.152E-05 | ENSG00000166106 | |
| chr19 | 999,961 | −0.021 | 2.233E−05 | ENSG00000116032 | |
| chr7 | 157,378,339 | 0.052 | 2.274E−05 | ENSG00000155093 | |
| chr17 | 16,540,132 | −0.270 | 2.365E−05 | ENSG00000197566 | |
| chr1 | 2,460,466 | 0.031 | 2.831E−05 | ENSG00000197921 | |
| chr14 | 59,113,371 | 0.253 | 2.918E−05 | ENSG00000165617 | |
| chr20 | 62,194,220 | 0.206 | 3.388E−05 | ENSG00000130589 | |
| chr6 | 7,441,846 | 0.068 | 3.433E−05 | ENSG00000124784 | |
| chr1 | 231,296,648 | 0.085 | 3.830E−05 | ENSG00000185880 | |
| chr1 | 2,475,177 | 0.062 | 4.081E−05 | ENSG00000197921 | |
| chr4 | 170,696,067 | 0.127 | 4.084E−05 | ENSG00000056050 | |
| chr1 | 231,296,641 | 0.084 | 5.177E−05 | ENSG00000185880 | |
| chr3 | 128,205,418 | 0.142 | 5.408E−05 | ENSG00000179348 | |
| chr19 | 999,937 | −0.019 | 5.557E−05 | ENSG00000116032 | |
| chr9a | 95,376,152 | 0.272 | 5.571E−05 | ENSG00000188312 | |
| ENSG00000127080 | |||||
| chr19 | 40,366,323 | 0.163 | 5.666E−05 | ENSG00000275395 | |
| chr20 | 60,886,354 | 0.031 | 5.690E−05 | ENSG00000130702 | |
| chr20 | 60,886,357 | 0.031 | 5.912E−05 | ENSG00000130702 | |
| chr19 | 40,366,308 | 0.163 | 5.921E−05 | ENSG00000275395 | |
| chr20 | 62,194,213 | 0.203 | 6.059E−05 | ENSG00000130589 | |
| chr12 | 2,903,464 | −0.062 | 6.221E−05 | ENSG00000256150 | |
| chr6 | 7,441,850 | 0.073 | 6.404E−05 | ENSG00000124784 | |
| chr22 | 50,985,408 | 0.046 | 6.716E−05 | ENSG00000130487 | |
| chr4 | 24,423,094 | 0.040 | 6.749E−05 | ENSG00000109819 | |
| chr5 | 170,068,701 | 0.044 | 7.195E−05 | ENSG00000182132 | |
| chr16 | 69,969,329 | 0.249 | 7.352E−05 | ENSG00000198373 | |
| chr20 | 60,886,348 | 0.031 | 7.884E−05 | ENSG00000130702 | |
| chr16 | 56,998,191 | 0.040 | 8.090E−05 | ENSG00000087237 | |
| chr9a | 95,376,137 | 0.283 | 8.368E−05 | ENSG00000188312 | |
| ENSG00000127080 | |||||
| chr12 | 133,341,501 | 0.039 | 8.446E−05 | ENSG00000176915 | |
| chr16 | 56,998,186 | 0.038 | 8.749E−05 | ENSG00000087238 | |
| chr20 | 62,194,202 | 0.202 | 8.765E−05 | ENSG00000130589 | |
| chr14 | 54,419,615 | 0.028 | 8.799E−05 | ENSG00000125378 | |
| chr19 | 3,823,080 | 0.041 | 9.100E−05 | ENSG00000105278 | |
| chr1 | 2,460,472 | 0.028 | 9.116E−05 | ENSG00000197921 | |
| chr19 | 40,366,341 | 0.162 | 9.234E−05 | ENSG00000275395 | |
| chr10 | 102,822,675 | 0.032 | 9.349E−05 | ENSG00000107821 | |
| chr17 | 40,825,688 | 0.030 | 9.473E−05 | ENSG00000068137 | |
| chr11 | 2,037,042 | 0.055 | 9.810E−05 | ENSG00000130600 |
NA not available.
aThe CpG sites annotated to two genes.
The top GREAT ontology enrichments for regions potentially related to depression by using binomial test.
| Ontology database | Term name | Binom FDR | Binom region fold enrichment |
|---|---|---|---|
| PANTHER | Transcription regulation by bZIP transcription factor | 1.94E−24 | 3.18 |
| PANTHER | Notch signaling pathway | 2.38E−07 | 1.81 |
| PANTHER | Nicotine pharmacodynamics pathway | 5.88E−06 | 1.85 |
| PANTHER | Huntington disease | 5.95E−06 | 1.38 |
| PANTHER | p53 pathway by glucose deprivation | 7.56E−05 | 2.03 |
| PANTHER | ATP synthesis | 7.44E−05 | 10.97 |
| PANTHER | Parkinson disease | 7.32E−05 | 1.45 |
| PANTHER | Hedgehog signaling pathway | 1.72E−04 | 1.76 |
| PANTHER | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | 1.31E−03 | 1.37 |
| PANTHER | Adrenaline and noradrenaline biosynthesis | 1.21E−02 | 1.59 |
| BioCyc | Histidine degradation III | 8.26E−09 | 7.34 |
| BioCyc | Palmitate biosynthesis I (animals) | 1.27E−08 | 3.92 |
| BioCyc | Catecholamine biosynthesis | 1.09E−08 | 6.49 |
| BioCyc | Adenine and adenosine salvage I | 2.15E−07 | 18.12 |
| BioCyc | Aspartate biosynthesis | 2.86E−07 | 8.98 |
| BioCyc | Methylglyoxal degradation VI | 4.68E−07 | 3.41 |
| BioCyc | Oxidized GTP and dGTP detoxification | 6.76E−07 | 18.79 |
| BioCyc | Hypusine biosynthesis | 8.58E−07 | 24.23 |
| BioCyc | Serine and glycine biosynthesis | 2.47E−06 | 3.16 |
| BioCyc | Dolichyl-diphosphooligosaccharide biosynthesis | 2.45E−06 | 3.50 |
| MSigDB | Elongation arrest and recovery | 1.03E−43 | 6.52 |
| MSigDB | Formation of tubulin folding intermediates by CCT/TriC | 6.80E−30 | 5.44 |
| MSigDB | Notch signaling pathway | 5.63E−28 | 2.85 |
| MSigDB | Prefoldin mediated transfer of substrate to CCT/TriC | 2.68E−26 | 4.43 |
| MSigDB | Thrombin signaling through proteinase activated receptors (PARs) | 3.13E−25 | 3.45 |
| MSigDB | Formation of RNA Pol II elongation complex | 3.55E−25 | 3.64 |
| MSigDB | Glucagon signaling in metabolic regulation | 1.69E−24 | 2.84 |
| MSigDB | PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase | 2.20E−23 | 2.67 |
| MSigDB | Prostacyclin signaling through prostacyclin receptor | 4.70E−22 | 4.40 |
| MSigDB | G alpha (12/13) signaling events | 3.12E−20 | 1.98 |
| GO-MF | DNA binding | 1.26E−114 | 1.36 |
| GO-MF | Nucleic acid binding | 1.06E−97 | 1.27 |
| GO-MF | Sequence-specific DNA binding transcription factor activity | 7.48E−98 | 1.46 |
| GO-MF | Nucleic acid binding transcription factor activity | 9.13E−96 | 1.46 |
| GO-MF | Sequence-specific DNA binding | 1.57E−90 | 1.54 |
| GO-MF | Organic cyclic compound binding | 1.75E−87 | 1.18 |
| GO-MF | Heterocyclic compound binding | 5.68E−87 | 1.18 |
| GO-MF | Transcription regulatory region DNA binding | 4.84E−58 | 1.61 |
| GO-MF | Regulatory region DNA binding | 1.72E−57 | 1.60 |
| GO-MF | Transcription regulatory region sequence-specific DNA binding | 1.64E−53 | 1.85 |
| GO-BP | RNA metabolic process | 1.71E−89 | 1.27 |
| GO-BP | Gene expression | 8.91E−88 | 1.26 |
| GO-BP | RNA biosynthetic process | 7.09E−87 | 1.30 |
| GO-BP | Transcription, DNA-dependent | 7.90E−86 | 1.30 |
| GO-BP | Regulation of macromolecule biosynthetic process | 2.51E−82 | 1.23 |
| GO-BP | Nucleobase-containing compound biosynthetic process | 5.60E−82 | 1.28 |
| GO-BP | Regulation of RNA biosynthetic process | 1.08E−81 | 1.24 |
| GO-BP | Nucleic acid metabolic process | 1.56E−80 | 1.23 |
| GO-BP | Organic cyclic compound biosynthetic process | 2.66E−79 | 1.26 |
| GO-BP | Regulation of RNA metabolic process | 7.78E−79 | 1.23 |
MF molecular function, BP biological process.
Fig. 2Differential methylation patterns for the identified differentially methylated regions (DMRs).
The horizontal axis shows the chromosome positions with the black point indicating each CpG, and the vertical axis shows the coefficient for the association of each CpG sites with depression score. The blue line indicates the methylation pattern for each DMR. BP, base pair; chr, chromosome.
The results of annotation to significant differentially methylated regions (DMRs) (slk corrected P-value < 0.05).
| DMR ID | Chromosome | Start | End | Length | Stouffer-Liptak-Kechris ( | Gene symbol | Location |
|---|---|---|---|---|---|---|---|
| 1 | chr6 | 7,441,772 | 7,441,894 | 11 | 0.001 | Near | |
| 2 | chr21 | 10,989,962 | 10,991,112 | 59 | 0.002 | At | |
| 3 | chr7 | 157,378,078 | 157,378,360 | 13 | 0.002 | At | |
| 4 | chr12 | 132,329,893 | 132,330,413 | 18 | 0.003 | At | |
| 5 | chr5 | 140,045,103 | 140,045,416 | 13 | 0.004 | At | |
| 6 | chr12 | 56,329,618 | 56,329,905 | 17 | 0.004 | At | |
| 7 | chr19 | 40,366,276 | 40,366,427 | 14 | 0.008 | At | |
| 8 | chr22 | 50,985,408 | 50,985,540 | 15 | 0.009 | At | |
| 9 | chr16 | 90,143,720 | 90,143,886 | 11 | 0.020 | At | |
| 10 | chr15 | 23,034,971 | 23,035,423 | 6 | 0.021 | At | |
| 11 | chr5 | 138,729,711 | 138,730,335 | 36 | 0.023 | At | |
| 12 | chr1 | 2,475,075 | 2,475,337 | 14 | 0.024 | At | |
| 13 | chr2 | 95,539,959 | 95,540,223 | 9 | 0.032 | At | |
| 14 | chr9 | 37,002,619 | 37,002,829 | 24 | 0.036 | At | |
| 15 | chr16 | 87,901,443 | 87,901,581 | 11 | 0.040 | At | |
| 16 | chr6 | 101,850,301 | 101,850,869 | 22 | 0.043 | At | |
| 17 | chr14 | 54,419,545 | 54,419,845 | 16 | 0.044 | At | |
| 18 | chr2 | 223,163,019 | 223,163,942 | 29 | 0.045 | At | |
| 19 | chr1 | 871,143 | 871,655 | 23 | 0.048 | At |
Fig. 3Relationships of consensus module eigengenes and external trait.
Each row in the table corresponds to a consensus module, and each column to a trait. Numbers in the table report the correlations of the corresponding module eigengenes and trait with the P-values printed below the correlations in parentheses. The table is color coded by correlation according to the color legend.
The results of GO function and KEGG pathway enrichment analysis for genes clustered in pink module by DAVID tool.
| Category | Term | Count | |
|---|---|---|---|
| KEGG | Neuroactive ligand–receptor interaction | 93 | 3.03E−14 |
| KEGG | Olfactory transduction | 99 | 5.04E−07 |
| KEGG | Nicotine addiction | 20 | 1.53E−06 |
| KEGG | Calcium signaling pathway | 49 | 4.49E−05 |
| KEGG | Morphine addiction | 30 | 5.49E−05 |
| KEGG | Glutamatergic synapse | 35 | 5.99E−05 |
| KEGG | ECM-receptor interaction | 28 | 1.62E−04 |
| KEGG | Serotonergic synapse | 33 | 1.98E−04 |
| KEGG | Maturity onset diabetes of the young | 12 | 8.83E−04 |
| KEGG | Retrograde endocannabinoid signaling | 29 | 9.61E−04 |
| BIOCARTA | Intrinsic prothrombin activation pathway | 10 | 1.61E−03 |
| KEGG | Bile secretion | 21 | 2.78E−03 |
| KEGG | GABAergic synapse | 23 | 7.88E−03 |
| KEGG | Linoleic acid metabolism | 11 | 8.60E−03 |
| BIOCARTA | Platelet amyloid precursor protein pathway | 7 | 8.88E−03 |
| KEGG | Steroid hormone biosynthesis | 17 | 1.17E−02 |
| KEGG | Complement and coagulation cascades | 19 | 1.42E−02 |
| GO-BP | Chemical synaptic transmission | 88 | 3.54E−13 |
| GO-BP | Potassium ion transmembrane transport | 45 | 2.07E−07 |
| GO-BP | Regulation of ion transmembrane transport | 41 | 9.55E−07 |
| GO-MF | G-protein coupled receptor activity | 167 | 1.73E−06 |
| GO-MF | Calcium ion binding | 165 | 7.84E−06 |
| GO-MF | Voltage-gated potassium channel activity | 24 | 2.58E−05 |
| GO-BP | G-protein coupled receptor signaling pathway | 199 | 3.06E−05 |
| GO-BP | Sodium ion import across plasma membrane | 10 | 9.99E−05 |
| GO-BP | Nervous system development | 74 | 1.54E−04 |
| GO-BP | G-protein coupled receptor signaling pathway | 19 | 2.83E−04 |
| GO-MF | Glutamate receptor activity | 8 | 6.30E−04 |
| GO-MF | GABA-A receptor activity | 10 | 1.83E−03 |
| GO-BP | Central nervous system development | 34 | 2.46E−03 |
MF molecular function, BP biological process.